Abstract
Purpose of Review The most common type of cardiac amyloidosis is transthyretin amyloidosis (ATTR-CM). Early forms of the disease can often go undetected. Effective pharmacological treatments are available for ATTR-CM. However, current treatment options may be more effective when used earlier in the disease, making early detection paramount. Below, we discuss updates with regards to the role that blood-based biomarkers play in detecting subclinical cardiac amyloidosis. Recent Findings Carriers of amyloidogenic mutations in the TTR gene are at a heightened risk of developing heart failure and have higher mortality rates compared with noncarrier counterparts. Conventional biomarkers, such as the cardiac troponins and natriuretic peptides, may be useful to monitor subclinical cardiac amyloidosis.